XBiotech Inc (NASDAQ: XBIT), a clinical-stage Biopharmaceutical Company engaged in developing and commercializing True Human monoclonal antibodies, has announced the signing of a definitive agreement with Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson (NYSE: JNJ), for the sale of its novel antibody...
Foamix and Menlo Therapeutics have signed a definitive merger agreement to form a biopharmaceutical Company focused on dermatological conditions. The combined entity will have a robust portfolio of diversified candidates, including an approved product and three late-stage clinical candidates. Foamix’s AMZEEQ™ (minocycline) topical foam, 4%, recently...
Acne is one of the most common skin disorders in the U.S affecting over 50 million people annually. An estimated 85% of young adults aged between 12-25 years suffer from it according to the Global Burden of Disease (GDB) study. The rise in androgen levels during puberty,...
